ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluticasone

Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.

Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 1, 2005150 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only580 open or runningphase 4since Feb 1, 2005Feb 1, 2005none ahead
Respirent Pharmaceuticalsits history only182 open or runningphase 3since Sep 17, 2018Sep 17, 2018none ahead
Teva Pharmaceutical Industriesits history only140 open or runningphase 4since Dec 11, 2020Nov 22, 2011none ahead
Viatrisits history only130 open or runningphase 4since Dec 16, 2016Nov 21, 2006none ahead
Optinose USits history only101 open or runningphase 3since Jun 13, 2012Jun 13, 2012Mar 31, 2028phase 3 · NCT06850805
Mundipharma60 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only31 open or runningphase 3since Sep 14, 2010Sep 14, 2010Aug 2028phase 3 · NCT06234345
Merckits history only30 open or runningphase 2since Oct 5, 2006Oct 5, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 5, 2016Jan 5, 2016none ahead

Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mundipharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2009First study: phase 2 study in AsthmaFirst studyNCT00995800 · 46 enrolled · Germany
  2. Dec 7, 2011Phase 3 study in AsthmaNCT01511367 · 498 enrolled · Bulgaria, Czechia, Hungary and more
  3. Jun 15, 2015Phase 4 study in AsthmaNCT02491970 · 15 enrolled
  4. Feb 8, 2016Phase 3 study in ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)NCT02693769 · 2 enrolled · Slovakia
  5. Nov 10, 2017Phase 3 study in AsthmaNCT03387241 · 330 enrolled · China
  6. Feb 11, 2020Phase 4 study in Persistent AsthmaNCT04271839

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Mundipharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04271839Persistent Asthma4WithdrawnMay 20210
NCT03387241Asthma · China3UNKNOWNDec 30, 2019330
NCT02693769ACOS (Fixed Airflow Obstruction and Elevated Eosinophils) · Slovakia3TerminatedOct 20162
NCT02491970Asthma4TerminatedApr 6, 201715
NCT01511367Asthma · Bulgaria, Czechia, Hungary and more3CompletedSep 2013498
NCT00995800Asthma · Germany2CompletedJul 201046

How it is read

Names in the registry

  • “Fluticasone Propionate”, 17 entries
  • “Fluticasone propionate”, 13 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “fluticasone propionate”, 7 entries
  • “fluticasone propionate/salmeterol”, 7 entries

Codes read as this program: NCX4251, FP100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.